Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.56
- Piotroski Score 2.00
- Grade Buy
- Symbol (SIBN)
- Company SI-BONE, Inc.
- Price $12.55
- Changes Percentage (2.12%)
- Change $0.26
- Day Low $12.12
- Day High $12.69
- Year High $21.70
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $18.50
- High Stock Price Target $25.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.08
- Trailing P/E Ratio -12.3
- Forward P/E Ratio -12.3
- P/E Growth -12.3
- Net Income $-43,336,000
Income Statement
Quarterly
Annual
Latest News of SIBN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SI-BONE Inc (SIBN) Q3 2024 Earnings Call Highlights: Record Revenue and Path to Profitability
SI-BONE's CFO expects continued growth and profitability driven by elevated physician interest, favorable reimbursement, and product expansion. The CEO notes strong demand for their solutions in the S...
By Yahoo! Finance | 1 week ago -
Shareholders in SI-BONE (NASDAQ:SIBN) are in the red if they invested three years ago
SI-BONE, Inc. (NASDAQ:SIBN) shares have risen 25% in the last month, but have declined by 47% over three years. Despite strong revenue growth of 21% annually, the market may not be fully valuing the c...
By Yahoo! Finance | 3 months ago
